Health Economics›Clear cell renal cell carcinoma›Metastatic disease first-line

Metastatic disease first-line

Clear cell renal cell carcinoma · 23 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 15 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Regorafenib monotherapy Variant #06	—	R 307 423	28d	~3.6 mo	~9.4 mo	~4	~R 1 229 690 PFS proxy · indirect	15
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	—	—	—	1
Cabozantinib, Ipilimumab, Nivolumab Variant #01 Partial	—	R 184 762	28d	—	—	—	—	1
Lenvatinib and Pembrolizumab Variant #01	—	R 128 546	21d	23.9 mo	—	35	R 4 499 104 PFS proxy	3
Axitinib and Pembrolizumab Variant #01	—	R 98 039	21d	15.7 mo	46.6 mo	23	R 2 254 887 PFS proxy	6
Cabozantinib monotherapy Variant #01	—	R 90 983	28d	8.6 mo	—	10	R 909 829 PFS proxy	2
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	—	52.7 mo	—	—	3
Bevacizumab monotherapy Variant #08	—	R 57 246	21d	8.5 mo	—	13	R 744 203 PFS proxy	1
Erlotinib and Bevacizumab Variant #01	—	R 52 071	28d	9.9 mo	—	11	R 572 783 PFS proxy	1
Everolimus and Lenvatinib Variant #01	—	R 48 788	21d	14.7 mo	—	22	R 1 073 328 PFS proxy	1
Sorafenib monotherapy Variant #04	—	R 37 339	28d	6.8 mo	23.3 mo	8	R 298 711 PFS proxy	4
Sunitinib monotherapy Variant #05	—	R 33 433	28d	9.1 mo	34.0 mo	10	R 334 331 PFS proxy	24
Cabozantinib and Nivolumab Variant #01 Partial	—	R 30 328	14d	16.6 mo	43.6 mo	37	R 1 122 122 PFS proxy	5
Pazopanib monotherapy Variant #01	—	R 22 754	28d	9.2 mo	22.9 mo	11	R 250 289 PFS proxy	3
Axitinib monotherapy Variant #01	—	R 21 402	28d	10.1 mo	21.7 mo	11	R 235 420 PFS proxy	2
Bevacizumab and Interferon alfa-2a Variant #01	—	R 19 082	14d	9.8 mo	20.8 mo	22	R 419 807 PFS proxy	4
Axitinib and Toripalimab Variant #01 Partial	—	R 16 051	21d	18.0 mo	—	27	R 433 386 PFS proxy	2
Gemcitabine and Sunitinib Variant #01	—	R 10 776	21d	—	—	—	—	—
Axitinib and Avelumab Variant #01 Partial	—	R 10 701	14d	13.6 mo	43.2 mo	30	R 321 027 PFS proxy	3
High-dose Interleukin-2 N/A - secondary systemic drug	—	R 43	28d	—	—	—	—	—
Interferon alfa-2a monotherapy Variant #01 Partial	—	—	7d	5.4 mo	21.3 mo	24	—	6
Placebo Partial	—	—	—	—	~15.2 mo	—	—	1
Tivozanib monotherapy Variant #01 Partial	—	—	28d	11.9 mo	—	13	—	1

23 of 23 regimens shown